drugset / Trial / NCT06638034
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
NaSingle-groupOpen-labelTreatment
Summary
FAP and RGD are overexpressed in many tumor tissues. This study is intended to conduct preliminary clinical transformation and internal irradiation dosimetry research on 177Lu-FAPI-RGD--a new dual-targeted 177Lu therapeutic drug for the first time in the world.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2025-01-01
- Completion
- 2025-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-FAPI-RGD | Unknown | 2220 mbq | Intravenous |
| Subject | 177Lu-FAPI-RGD | Unknown | 3330 mbq | Intravenous |
| Subject | 68Ga-FAPI-RGD | Diagnostic / imaging agent | — | — |
Indications
No indication recorded.